Electric fields with immunotherapy and chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 22 or older in the US, or 18 or older elsewhere.
- Diagnosed with stage 4 non-small cell lung cancer (squamous or non-squamous type).
- Have tumors in the chest that can be measured or seen on scans.
- Have not had any prior treatment for cancer that has spread.
- Good physical condition (able to do daily activities without help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a device that sends low-energy electrical fields (called Tumor Treating Fields) to the lung tumor before surgery. The goal is to see if it can help shrink the tumor and improve surgical outcomes.
This trial tests a new treatment called pulsed electric field therapy for people with advanced lung cancer (stage III or IV) that has not responded to first-line immunotherapy. It uses targeted electrical pulses to destroy tumor cells, and may be an option for those who still have other measurable tumors.
This trial tests whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels and at least one large tumor. It is for people who have not had treatment before and cannot have curative surgery or radiation.
This pilot study tests a device-based therapy (“Tumor Treating Fields,” TTFields) in people with non-small cell lung cancer (NSCLC) who have an EGFR mutation. The study aims to understand how this treatment affects outcomes and whether it can be done safely.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
Hear when a new Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.